Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
-
Value Traded
-
Short % Float
-
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
-
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
-
Float Shares
-
Insiders
-
Institutions
-
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
PRTCY Catalyst Timeline
Dated clinical, regulatory and corporate events for PureTech Health plc
Catalyst Timeline
Dated clinical, regulatory & corporate events for PureTech Health plc
10Total events
2Upcoming
1Tier-1 (high impact)
2026 to 2027Coverage
Upcoming catalysts 2
Event history 5
▲Full ResultsLYT-200Clinical Data
Detailed Phase 1b results including depth of response and safety across 101 patients
relapsed/refractory high-risk myelodysplastic syndromes (HR-MDS) and acute myeloid leukemia (AML)source ↗
▲Oral PresentationLYT-200Presentation
Phase 1b results for LYT-200 presented orally at ESMO 2026
relapsed/refractory high-risk myelodysplastic syndromes (HR-MDS) and acute myeloid leukemia (AML)source ↗
◆Oral PresentationLYT-200Presentation
Phase 1b topline results for LYT-200 in R/R HR-MDS and AML presented at ESMO 2026
relapsed/refractory high-risk myelodysplastic syndromes (HR-MDS) and acute myeloid leukemia (AML)source ↗
▲End Of Phase 1 MeetingLYT-200FDA Meeting
Successful completion of End-of-Phase 1 meeting with U.S. FDA for LYT-200 in R/R HR-MDS
relapsed/refractory (R/R) high-risk myelodysplastic syndromes (HR-MDS)source ↗
▲Fast Track DesignationLYT-200Designation
FDA Fast Track designation granted for LYT-200 plus HMA in R/R HR-MDS
relapsed/refractory (R/R) high-risk myelodysplastic syndromes (HR-MDS)source ↗
Past FDA Catalysts and PDUFA Decisions
How PRTCY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 65%
Micro Cap(rank 447 of 687)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Deupirfenidone Small MoleculesNCT05321420 | Idiopathic Pulmonary Fibrosis | Phase 3 | ACTIVE NOT_RECRUITING | 1,340 | Dec 31, 2025 | ||||||
| LYT-200 Small MoleculesCompletedNCT04666688 | Metastatic Cancer | Phase 1/2 | COMPLETED | 44 | Dec 12, 2024 | ||||||
| LYT-200 Small MoleculesCompletedNCT05829226 | AML, Adult Recurrent | Phase 1 | COMPLETED | 101 | Dec 31, 2025 | ||||||
| LYT-300 Small MoleculesCompletedNCT05129865 | Undisclosed | Phase 1/2 | COMPLETED | 186 | Oct 23, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every PRTCY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in PRTCY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PRTCY for Q2 2026. | ||||
Ownership Trends
PRTCY Short Interest
Shares sold short, counted twice a month.
-
Short % of Float
of tradable shares sold short
5.4K
Shares Sold Short
-5.0% vs prior count
-
Days to Cover
trading days of normal volume to buy every short share back
546
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PRTCY ranks across every disease it competes in
Competitive Position is a premium feature
See how PRTCY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPRTCY News
-PRTCY
Oct 26, 2026PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026
PureTech Health presented Phase 1b results for LYT-200 at ESMO 2026, showing promising responses in patients with relapsed/refractory high-risk myelodysplastic syndromes and acute myeloid leukemia. The trial demonstrated a favorable safety profile with no serious adverse events. Following a successful FDA meeting, LYT-200 will advance to Phase 2 trials.
Read more →-PRTCY
Oct 19, 2026PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026
PureTech Health announced positive Phase 1b results for LYT-200 in treating relapsed/refractory high-risk myelodysplastic syndromes and acute myeloid leukemia. The results indicate encouraging clinical activity and a favorable safety profile. The company plans to advance LYT-200 into a Phase 2 trial following a successful FDA meeting and Fast Track designation.
Read more →-PRTCY
Sep 21, 2026PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS)
PureTech Health announced a successful End-of-Phase 1 meeting with the FDA and received Fast Track designation for LYT-200, aimed at treating relapsed/refractory high-risk myelodysplastic syndromes. The upcoming Phase 2 STRIDE-MDS trial will evaluate LYT-200's efficacy in approximately 125 patients. Positive results from the Phase 1b trial support this advancement.
Read more →About PureTech Health plc
BIOPHARMAWATCH ELITE
Trade the next PRTCY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime